Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data agilon health, inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
794
1,218
1,521
2,388
4,316
6,061
5,933
General and administrative
123
137
428
208
286
269
239
Operating expenses
901
1,275
2,228
2,829
Operating income
-107
-56.7
-372
-105
-232
-292
-463
Interest expense
9.07
8.14
6.15
4.48
6.66
6.18
6.64
Other non-operating income
0.96
2.47
2.18
13.9
27.8
34.5
67.6
Pre-tax income
-115
-62.3
-383
-90.7
-194
-249
-404
Income tax
-0.23
0.87
0.89
1.64
0.79
1.45
1.25
Income from continuing operations
-384
-92
-195
-250
-405
Net income to minority interests
-0.15
0
-0.3
-0.31
-0.21
0.05
0
Net income
-283
-60.1
-406
-107
-263
-260
-391
EBITDA
-65.2
-42.6
-358
-91.6
-212
-268
-435
Shares, basic (weighted)
295
323
373
408
409
411
414
Shares, diluted (weighted)
295
323
373
408
409
411
414
Balance sheet
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
139
107
1,040
465
108
188
174
Short-term investments
0
412
Receivables
145
293
492
942
1,017
674
Other current assets
9.64
19
31.6
42.5
35.1
138
Total current assets
294
1,367
1,451
1,480
1,458
1,097
Property, plant and equipment
6.46
9.16
19.9
27.6
28.2
25.4
Lease right-of-use assets
11.7
12
13.4
8.78
3.54
Goodwill
41.5
41.5
2.51
24.1
24.1
0
Intangible assets
60.5
55.4
18.4
63.8
72.8
65.7
Other non-current assets
43.7
113
106
145
151
83.5
Total assets
446
1,586
1,697
1,741
1,734
1,271
Accounts payable
97.2
113
177
239
220
127
Short-term debt
3.04
5
5
6.25
0
19.2
Total current liabilities
267
357
535
977
1,152
1,076
Long-term debt
64.7
43.4
38.5
32.3
34.9
15.8
Lease liabilities
5.51
7.9
9.09
10.9
6.6
1.83
Other non-current liabilities
90.1
94.3
82.5
70.4
76.1
52.3
Total liabilities
422
495
657
1,080
1,263
1,145
Total debt
67.7
48.8
43.8
38.6
34.9
35
Paid-in capital
264
2,046
2,107
1,987
2,054
2,104
Retained earnings
-551
-958
-1,064
-1,327
-1,587
-1,978
Other comprehensive income
0
-5.56
-2.3
-0.09
0.92
Shareholders' equity
-285
1,092
1,041
662
471
Minority interests
0
-0.3
-0.61
-0.82
0
Total equity
-232
-285
1,092
1,041
661
471
127
Total liabilities and equity
446
1,586
1,697
1,741
1,734
1,271
Shares outstanding
249
400
412
406
412
16.6
Cash flow statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-283
-60.1
-407
-107
-263
-260
-391
Depreciation and amortization
41.4
14.1
14.7
13.8
20.2
24.5
28.6
Stock-based compensation
5.23
6.69
292
28.4
69.5
50.7
49.1
Deferred income tax
-0.23
0.01
-0.4
0.53
-1.6
0.22
-0.24
Change in receivables
-23.3
-59.4
-149
-204
-460
-74.6
345
Change in payables
18.5
24.9
19.4
65.7
32.1
4.64
-85.6
Cash from operations
-104
-53.2
-148
-131
-156
-57.8
-106
Capital expenditures
-2.89
-1.78
-6.56
-15.4
-15.8
-13.3
-13.2
Acquisitions
0
-45.3
0
0
Purchases of investments
0
0
-458
-115
-12
-60.2
Sales and maturities of investments
2.06
7.1
52.5
164
207
194
Cash from investing
-5.06
22.1
-90.5
-444
-44
140
88.6
Debt issued
0
0
100
0
0
Debt repaid
-3.59
-3.04
-120
-5
-5
-3.75
0
Stock issued
180
34.4
18.1
33.1
11.9
1.17
Share buybacks
0
-6.7
0
0
-200
0
0
Cash from financing
176
24.6
1,154
28.1
-193
-2.58
-2.99
Net change in cash
67.4
-6.52
916
-547
-393
79.5
-20.1
Free cash flow
-107
-55
-155
-146
-172
-71
-119
Interest paid
8.04
7.09
4.82
3.67
5.8
4.6
5.66
Income taxes paid
0.03
0
1.82
5.31
5.4
1.8
0.58
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $80.73 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-5.2%
Operating income / revenue.
EBITDA margin
-4.8%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-4.2%
Pre-tax income / revenue.
Net margin
-3.9%
Net income / revenue.
FCF margin
-1.4%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-1.2%
Cash from operations / revenue.
Return on assets (ROA)
-14.6%
Net income / average total assets.
Stock-based pay / revenue
0.8%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.2%
Capital expenditures / revenue.
D&A / revenue
0.5%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-2.1%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
35.4%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
37.2%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-26.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-9.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
23.3%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
0.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
0.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
5.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.08x
Current assets / current liabilities.
Quick ratio
0.89x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.08x
(Cash + short-term investments) / current liabilities.
Debt / assets
1.9%
Total debt / total assets.
Liabilities / assets
85.7%
Total liabilities / total assets.
Net debt
-$76.9M
Total debt - cash - short-term investments. Negative means more cash than debt.
Interest coverage
-44.4x
Operating income / interest expense.
Working capital
$106.2M
Current assets - current liabilities.
Goodwill and intangibles / assets
3.8%
(Goodwill + intangible assets) / total assets.
Efficiency
Metric
Value
How it is calculated
Asset turnover
3.72x
Revenue / average total assets.
Fixed asset turnover
242x
Revenue / average property, plant and equipment.
Receivables turnover
5.59x
Revenue / average receivables.
Days sales outstanding
65 days
365 x average receivables / revenue.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$13.49
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Market cap + total debt - cash - short-term investments.
P/S
0.23x
Market cap / revenue.
EV/Sales
0.22x
Enterprise value / revenue.
FCF yield
-6.3%
Free cash flow / market cap.
Earnings yield
-17.1%
Net income / market cap (the inverse of P/E).
What was agilon health, inc.'s revenue in fiscal 2025?
agilon health, inc. reported revenue of $5.93B for fiscal 2025, 2.1% lower than the year before.
Was agilon health, inc. profitable in fiscal 2025?
No. It reported a net loss of $391.3M.
How much free cash flow did agilon health, inc. generate in fiscal 2025?
Cash from operations of $105.8M minus capital expenditures of $13.2M left free cash flow of -$119.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.